Lupin gets USFDA nod for generic antibiotic

05 Dec 2011 Evaluate

Lupin Ltd has received final approval from the US health regulator for its generic antibiotic minocycline hydrochloride extended-release tablets used for treating acne. The approval by the US Food and Drug Administration (USFDA) has been granted to the company’s subsidiary, Lupin Pharmaceuticals Inc, for tablets of 65 mg, 80 mg, 105 mg and 115 mg strengths. The tablets are generic versions of Medicis Pharmaceutical Corporation’s patented drug Solodyn.

It is an oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older. Citing market research firm IMS’ September 2011 data, the company said Solodyn had sales of $750 million.

Lupin Share Price

2340.75 39.05 (1.70%)
10-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1813.00
Dr. Reddys Lab 1313.90
Cipla 1333.10
Zydus Lifesciences 922.90
Lupin 2340.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×